Valuation: Verastem, Inc.

Market Cap 596M 515M 484M 440M 827M 56.98B 841M 5.67B 2.22B 28.53B 2.24B 2.19B 94.82B P/E 2026 *
-4.1x
P/E 2027 * -5.65x
Enterprise Value 638M 551M 518M 471M 885M 60.99B 900M 6.07B 2.37B 30.54B 2.39B 2.34B 101B EV / Sales 2026 *
5.48x
EV / Sales 2027 * 3.29x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-2.37%
Current month+13.45%
1 month+14.04%
3 months+52.31%
6 months+13.06%
Current year-14.77%
1 week 6.44
Extreme 6.44
7.18
1 month 5.54
Extreme 5.54
7.18
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-2.37%-19.95%-31.39% 596M
-1.90%+2.85%+62.82%+104.39% 70.07B
+8.35%+3.16%+37.98%+73.28% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+2.26%+0.09%+48.90%+11.90% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+2.47%+4.07%+37.51%-16.51% 18.75B
+0.38%-1.14%+16.94%+567.31% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +1.43%-1.04%+46.32%+176.27% 26.43B
Weighted average by Cap. +1.79%-1.41%+51.54%+162.79%

Financials

2026 *2027 *
Net sales 116M 101M 94.51M 85.95M 162M 11.13B 164M 1.11B 433M 5.58B 437M 428M 18.53B 181M 156M 147M 134M 251M 17.32B 255M 1.72B 673M 8.67B 680M 665M 28.82B
Net income -166M -143M -135M -122M -230M -15.86B -234M -1.58B -617M -7.94B -623M -609M -26.4B -157M -136M -127M -116M -218M -15.02B -222M -1.49B -584M -7.52B -590M -577M -24.99B
Net Debt 41.9M 36.19M 34.01M 30.93M 58.15M 4.01B 59.1M 398M 156M 2.01B 157M 154M 6.67B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
14/08/26 USD 6.580 -1.35% 1,280,177
13/08/26 USD 6.670 -4.03% 1,856,897
12/08/26 USD 6.950 -1.42% 1,263,817
11/08/26 USD 7.050 +3.83% 2,087,689
10/08/26 USD 6.790 +0.74% 2,298,110
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.580USD
Average target price
14.75USD
Spread / Average Target
+124.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock